Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor.
Zhao, Y., Zhou, B., Bai, L., Liu, L., Yang, C.Y., Meagher, J.L., Stuckey, J.A., McEachern, D., Przybranowski, S., Wang, M., Ran, X., Aguilar, A., Hu, Y., Kampf, J.W., Li, X., Zhao, T., Li, S., Wen, B., Sun, D., Wang, S.(2018) J Med Chem 61: 6110-6120
- PubMed: 30015487 
- DOI: 10.1021/acs.jmedchem.8b00483
- Primary Citation of Related Structures:  
6C7Q, 6C7R - PubMed Abstract: 
We report the structure-based discovery of CF53 (28) as a highly potent and orally active inhibitor of bromodomain and extra-terminal (BET) proteins. By the incorporation of a NH-pyrazole group into the 9H-pyrimido[4,5- b]indole core, we identified a series of compounds that bind to BRD4 BD1 protein with K i values of <1 nM and achieve low nanomolar potencies in the cell growth inhibition of leukemia and breast cancer cells ...